These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. 19 Schiff bases as antimycobacterial agents: synthesis, molecular docking and a plausible mechanism of action. Cai YX; Chen JX; Dong HM; Yang ZC Future Med Chem; 2024 Mar; 16(5):453-467. PubMed ID: 38314562 [TBL] [Abstract][Full Text] [Related]
24. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis. Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494 [TBL] [Abstract][Full Text] [Related]
25. Anti-Tuberculosis Potential of OJT008 against Active and Multi-Drug-Resistant Mycobacterium Tuberculosis: In Silico and In Vitro Inhibition of Methionine Aminopeptidase. Onyenaka C; Idowu KA; Ha NP; Graviss EA; Olaleye OA Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138972 [TBL] [Abstract][Full Text] [Related]
26. Deb PK; Al-Shar'i NA; Venugopala KN; Pillay M; Borah P J Enzyme Inhib Med Chem; 2021 Dec; 36(1):869-884. PubMed ID: 34060396 [TBL] [Abstract][Full Text] [Related]
27. Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid. Pereira JH; de Oliveira JS; Canduri F; Dias MV; Palma MS; Basso LA; Santos DS; de Azevedo WF Acta Crystallogr D Biol Crystallogr; 2004 Dec; 60(Pt 12 Pt 2):2310-9. PubMed ID: 15583379 [TBL] [Abstract][Full Text] [Related]
28. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase. Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243 [TBL] [Abstract][Full Text] [Related]
29. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques. Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798 [TBL] [Abstract][Full Text] [Related]
30. Identification of New Almeleebia TM; Shahrani MA; Alshahrani MY; Ahmad I; Alkahtani AM; Alam MJ; Kausar MA; Saeed A; Saeed M; Iram S Molecules; 2021 Apr; 26(8):. PubMed ID: 33923734 [No Abstract] [Full Text] [Related]
31. One-Pot Synthesis of Novel Hydrazono-1,3-Thıazolıdın-4-One Derivatives as Anti-HIV and Anti-Tubercular Agents: Synthesıs, Bıologıcal Evaluatıon, Molecular Modelling and Admet Studıes. Pasha MA; Mondal S; Panigrahi N; Shetye G; Ma R; Franzblau SG; Zheng YT; Murugesan S Curr HIV Res; 2022; 20(3):255-271. PubMed ID: 35549861 [TBL] [Abstract][Full Text] [Related]
34. Shikimate kinase, a protein target for drug design. Coracini JD; de Azevedo WF Curr Med Chem; 2014; 21(5):592-604. PubMed ID: 24164195 [TBL] [Abstract][Full Text] [Related]
35. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants. Jagadeb M; Rath SN; Sonawane A J Cell Biochem; 2018 Sep; 119(9):7328-7338. PubMed ID: 29761826 [TBL] [Abstract][Full Text] [Related]
36. In silico identification of potential inhibitors against shikimate dehydrogenase through virtual screening and toxicity studies for the treatment of tuberculosis. Isa MA; Majumdar RS; Haider S Int Microbiol; 2019 Mar; 22(1):7-17. PubMed ID: 30810932 [TBL] [Abstract][Full Text] [Related]
37. Discovery and evaluation of novel Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors as therapeutic drug leads. Krishna VS; Zheng S; Rekha EM; Guddat LW; Sriram D J Comput Aided Mol Des; 2019 Mar; 33(3):357-366. PubMed ID: 30666485 [TBL] [Abstract][Full Text] [Related]
38. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis. Saharan VD; Mahajan SS Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201 [TBL] [Abstract][Full Text] [Related]
39. Proteomic characterization of Mycobacterium tuberculosis reveals potential targets of bostrycin. Yuan P; He L; Chen D; Sun Y; Ge Z; Shen D; Lu Y J Proteomics; 2020 Feb; 212():103576. PubMed ID: 31706025 [TBL] [Abstract][Full Text] [Related]
40. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]